ReviewMetabolic brain disease2025
Mushrooms for the brain: A review of the neuroprotective effects of mushroom bioactive compounds.
Review in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative and neuropsychiatric diseases pose significant challenges to individuals' well-being and healthcare systems. These conditions share common mechanisms like oxidative stress, protein aggregation, inflammation, impaired neurotransmission, mitochondrial dysfunction, and excitotoxicity. Current treatments offer limited efficacy and often come with adverse effects. Mushrooms, recognized as a valuable cultural and nutritional resource, hold therapeutic potential. As a future superfood, they contribute to overall health and well-being. Various mushroom groups have been studied for their bioactive compounds, including polysaccharides, protein complexes, peptides, terpenoids, and phenolic compounds, demonstrating efficacy in different neurodegenerative conditions. Notably, edible mushrooms have shown promise in mitigating beta-amyloid-induced neurotoxicity. This review explores the utilization of mushroom biomolecules in treating neurodegenerative diseases, offering novel research insights with preclinical and clinical trials in both rat model and humans paving the way for the development and utilization of mushroom bioactive compounds as neuroprotective agents.
Indexed as
Identifiers
41060489What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.